ArticleBiomolecules & biomedicine2025
Retraction: Tocilizumab inhibits neuronal cell apoptosis and activates STAT3 in cerebral infarction rat model.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retraction: Tocilizumab inhibits neuronal cell apoptosis and activates STAT3 in cerebral infarction rat model.Biomolecules & biomedicine · 2025Article
Corrections and comments
- Retraction of
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retracted article: https://www.bjbms.org/ojs/index.php/bjbms/article/view/853 Following publication, concerns were raised by readers and the public regarding the integrity of the data presented in two figures of this article: Figure 2B: An unexpected overlap was found between an image presented in this study and figures published in other articles. Figure 4: An unexpected overlap was detected within the Western blot panels, suggesting potential duplication or manipulation. The editorial office contacted all authors on 13 January 2025 and 30 January 2025 to clarify these concerns. On 4 March 2025, the corresponding author was specifically approached through both the e-mail address provided upon article submission and an institutional e-mail located online. However, no response or explanation was ever received. Following our journal's policies and guidelines from the Committee on Publication Ethics (COPE), the editors have decided to retract the article from publication due to serious concerns about the reliability and originality of the data. This retraction is intended to maintain the integrity of the scientific record. We apologize to the readership for any inconvenience caused. We thank the individuals who brought these concerns to our attention. The Editor-in-Chief has approved this retraction note.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.